Complete Response Letter is related to the request for additional data and analyses. F2G remains committed to bringing olorofim to patients and intends to meet with FDA in the coming months to align on next steps to obtain approval using the full…Original Article
You may also like
UroGen Submits Completed UGN-102 NDA Seeking Approval...
FDA Accepts LEO Pharma’s Filing of Delgocitinib...
Iterum Therapeutics Provides Update on FDA Advisory...
AbbVie Submits Biologics License Application to the...
PTC Therapeutics Announces FDA Acceptance for Filing...
Stealth BioTherapeutics Announces Positive Vote from...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.